Veravas launched in 2017 with a mission that went far beyond just selling technology or building products. We want to impact healthcare, raising the bar for diagnostic accuracy, efficacy, and the scope of what can be tested. Below are some milestones and inflection points in this journey.
Veravas, Inc. and Tymora Analytical Operations, LLC announced today that they have entered into a strategic alliance to explore the integration of their respective technologies. Together, they will aim to enrich and measure circulating biomarkers for use in non-invasive early-stage Alzheimer’s Disease (AD) diagnostics and other applications in the global life sciences research and clinical in vitro diagnostics markets.
Today, the FDA issued an updated warning of biotin interference with certain laboratory tests. The FDA remains concerned about certain laboratory tests that have not addressed the risk of biotin interference. For example, the FDA has continued to receive adverse events reports indicating biotin interference caused falsely low troponin results.
Register to receive updates and more information as it becomes available – from product launches to conference posters to novel partnerships and events.